- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Binding Immunoglobulin Protein.
Displaying page 1 of 1.
EudraCT Number: 2015-000479-28 | Sponsor Protocol Number: LTS13932 | Start Date*: 2015-08-17 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | |||||||||||||
Medical condition: Acute Myeloid Leukemia NOS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001923-11 | Sponsor Protocol Number: Nef-202 | Start Date*: 2012-10-17 | |||||||||||
Sponsor Name:Pharmalink AB | |||||||||||||
Full Title: A Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primar... | |||||||||||||
Medical condition: Primary IgA nephropathy patients at risk of developing end stage renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) CZ (Completed) DE (Completed) BE (Completed) SE (Completed) DK (Completed) IT (Completed) GB (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000785-18 | Sponsor Protocol Number: HIPRA-HH-4 | Start Date*: 2022-05-09 | |||||||||||
Sponsor Name:HIPRA SCIENTIFIC | |||||||||||||
Full Title: A Phase III, open label, single arm, multi-center, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1... | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001040-10 | Sponsor Protocol Number: CoVVac | Start Date*: 2021-04-26 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study | |||||||||||||
Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007789-51 | Sponsor Protocol Number: B1971005(6108A1-2001-WW) | Start Date*: 2009-03-23 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µ... | |||||||||||||
Medical condition: The test is a vaccine. The subjects are healthy adolescents. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003561-17 | Sponsor Protocol Number: ECP-002 | Start Date*: 2013-08-09 | |||||||||||
Sponsor Name:Edimer Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 open-label, dose-escalation study to evaluate the safety, pharmacokinetics, immunogeniticy and pharmacodynamics/efficacy of EDI200, an EDA-A1 replacement protein, administered to male inf... | |||||||||||||
Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1.... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003535-30 | Sponsor Protocol Number: 2018_16 | Start Date*: 2019-05-03 | |||||||||||
Sponsor Name:CHRU de Lille | |||||||||||||
Full Title: A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are... | |||||||||||||
Medical condition: A Phase III Study Comparing Lenalidomide and Daratumumab (R-Dara) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dos... | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002532-23 | Sponsor Protocol Number: ER004-CLIN01/F60082AI201 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:EspeRare Foundation [...] | |||||||||||||
Full Title: A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-link... | |||||||||||||
Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) | |||||||||||||
|
|||||||||||||
Population Age: In utero, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001205-23 | Sponsor Protocol Number: OVERLORD-MS | Start Date*: 2020-07-10 | |||||||||||
Sponsor Name:Helse Bergen HF, Haukeland University Hospital | |||||||||||||
Full Title: Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) | |||||||||||||
Medical condition: Remitting Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000753-28 | Sponsor Protocol Number: 212494 | Start Date*: 2021-05-05 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination of GSK’s RSVPreF3 OA investigational vaccine in ... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Ongoing) DE (Ongoing) IT (Ongoing) SE (Prematurely Ended) HU (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.